Paul Matteis
Stock Analyst at Stifel
(2.26)
# 1,485
Out of 4,424 analysts
75
Total ratings
38.33%
Success rate
-0.28%
Average return
Main Sectors:
28 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $26 → $21 | $16.08 | +30.64% | 4 | May 9, 2024 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $29 | $15.94 | +81.99% | 1 | Apr 30, 2024 | |
| ANRO Alto Neuroscience | Reiterates: Buy | $32 | $13.87 | +130.80% | 2 | Mar 25, 2024 | |
| DYN Dyne Therapeutics | Maintains: Buy | $35 → $41 | $26.01 | +57.63% | 2 | Mar 6, 2024 | |
| NGNE Neurogene | Initiates: Buy | $31 | $33.80 | -8.28% | 1 | Jan 5, 2024 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Buy | $101 | $81.66 | +23.68% | 5 | Dec 21, 2023 | |
| SAGE Sage Therapeutics | Maintains: Hold | $22 → $20 | $12.42 | +61.03% | 4 | Dec 18, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $141 → $144 | $140.11 | +2.78% | 5 | Dec 18, 2023 | |
| IONS Ionis Pharmaceuticals | Maintains: Hold | $45 → $50 | $39.94 | +25.19% | 3 | Dec 18, 2023 | |
| BIIB Biogen | Maintains: Buy | $315 → $287 | $219.54 | +30.73% | 6 | Dec 14, 2023 | |
| ALEC Alector | Upgrades: Buy | $8 → $15 | $5.17 | +190.14% | 3 | Dec 14, 2023 | |
| LXEO Lexeo Therapeutics | Initiates: Buy | $20 | $13.62 | +46.84% | 1 | Nov 28, 2023 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Hold | $373 | $417.65 | -10.69% | 12 | Nov 22, 2023 | |
| VTGN VistaGen Therapeutics | Initiates: Buy | $12 | $4.50 | +166.67% | 1 | Nov 14, 2023 | |
| NMRA Neumora Therapeutics | Initiates: Buy | $26 | $9.60 | +170.83% | 1 | Oct 10, 2023 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Buy | $240 | $151.33 | +58.59% | 6 | Sep 14, 2023 | |
| PEPG PepGen | Reiterates: Buy | $24 | $13.97 | +71.80% | 2 | Jun 14, 2023 | |
| ALKS Alkermes | Maintains: Hold | $31 → $33 | $24.36 | +35.50% | 4 | Jun 6, 2023 | |
| CERE Cerevel Therapeutics Holdings | Maintains: Buy | $50 → $54 | $41.92 | +28.83% | 2 | Aug 9, 2022 | |
| ATHA Athira Pharma | Downgrades: Hold | $36 → $5 | $2.13 | +134.74% | 2 | Jun 23, 2022 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $54 → $32 | $12.00 | +166.67% | 1 | Jun 8, 2022 | |
| VIGL Vigil Neuroscience | Initiates: Buy | $24 | $3.58 | +570.39% | 1 | Feb 1, 2022 | |
| ELYM Eliem Therapeutics | Initiates: Buy | n/a | $9.56 | - | 1 | Sep 7, 2021 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | n/a | $3.40 | - | 1 | Jul 26, 2021 | |
| GHRS GH Research | Initiates: Buy | n/a | $12.09 | - | 1 | Jul 20, 2021 | |
| AVDL Avadel Pharmaceuticals | Initiates: Buy | n/a | $15.55 | - | 1 | Mar 12, 2020 | |
| WVE Wave Life Sciences | Maintains: Outperform | n/a | $5.73 | - | 1 | Feb 21, 2018 | |
| CDTX Cidara Therapeutics | Initiates: Outperform | $340 | $13.57 | +2,405.53% | 1 | Dec 21, 2016 |
ACADIA Pharmaceuticals
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $16.08
Upside: +30.64%
Contineum Therapeutics
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $15.94
Upside: +81.99%
Alto Neuroscience
Mar 25, 2024
Reiterates: Buy
Price Target: $32
Current: $13.87
Upside: +130.80%
Dyne Therapeutics
Mar 6, 2024
Maintains: Buy
Price Target: $35 → $41
Current: $26.01
Upside: +57.63%
Neurogene
Jan 5, 2024
Initiates: Buy
Price Target: $31
Current: $33.80
Upside: -8.28%
BioMarin Pharmaceutical
Dec 21, 2023
Reiterates: Buy
Price Target: $101
Current: $81.66
Upside: +23.68%
Sage Therapeutics
Dec 18, 2023
Maintains: Hold
Price Target: $22 → $20
Current: $12.42
Upside: +61.03%
Neurocrine Biosciences
Dec 18, 2023
Maintains: Buy
Price Target: $141 → $144
Current: $140.11
Upside: +2.78%
Ionis Pharmaceuticals
Dec 18, 2023
Maintains: Hold
Price Target: $45 → $50
Current: $39.94
Upside: +25.19%
Biogen
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $219.54
Upside: +30.73%
Alector
Dec 14, 2023
Upgrades: Buy
Price Target: $8 → $15
Current: $5.17
Upside: +190.14%
Lexeo Therapeutics
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $13.62
Upside: +46.84%
Vertex Pharmaceuticals
Nov 22, 2023
Reiterates: Hold
Price Target: $373
Current: $417.65
Upside: -10.69%
VistaGen Therapeutics
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $4.50
Upside: +166.67%
Neumora Therapeutics
Oct 10, 2023
Initiates: Buy
Price Target: $26
Current: $9.60
Upside: +170.83%
Alnylam Pharmaceuticals
Sep 14, 2023
Reiterates: Buy
Price Target: $240
Current: $151.33
Upside: +58.59%
PepGen
Jun 14, 2023
Reiterates: Buy
Price Target: $24
Current: $13.97
Upside: +71.80%
Alkermes
Jun 6, 2023
Maintains: Hold
Price Target: $31 → $33
Current: $24.36
Upside: +35.50%
Cerevel Therapeutics Holdings
Aug 9, 2022
Maintains: Buy
Price Target: $50 → $54
Current: $41.92
Upside: +28.83%
Athira Pharma
Jun 23, 2022
Downgrades: Hold
Price Target: $36 → $5
Current: $2.13
Upside: +134.74%
KalVista Pharmaceuticals
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $12.00
Upside: +166.67%
Vigil Neuroscience
Feb 1, 2022
Initiates: Buy
Price Target: $24
Current: $3.58
Upside: +570.39%
Eliem Therapeutics
Sep 7, 2021
Initiates: Buy
Price Target: n/a
Current: $9.56
Upside: -
Acumen Pharmaceuticals
Jul 26, 2021
Initiates: Buy
Price Target: n/a
Current: $3.40
Upside: -
GH Research
Jul 20, 2021
Initiates: Buy
Price Target: n/a
Current: $12.09
Upside: -
Avadel Pharmaceuticals
Mar 12, 2020
Initiates: Buy
Price Target: n/a
Current: $15.55
Upside: -
Wave Life Sciences
Feb 21, 2018
Maintains: Outperform
Price Target: n/a
Current: $5.73
Upside: -
Cidara Therapeutics
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $13.57
Upside: +2,405.53%